LNK-01002

N/A

Report date: 2026/02/10 20:00:22
NME

Base Information

Drug NameLNK-01002
Drug Alias NameLNK01002LNK-1000318
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase JAK1 inhibitorsTyrosine-protein kinase JAK2 inhibitorsTyrosine-protein kinase receptor FLT3 inhibitors
TargetsTyrosine-protein kinase JAK1Tyrosine-protein kinase JAK2Tyrosine-protein kinase receptor FLT3
Therapy Area/IndicationsPrimary MyelofibrosisMyeloproliferative DisordersThrombocythemia, Essential +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesLynk Pharmaceutical (Hangzhou) Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesLynk Pharmaceutical (Hangzhou) Co Ltd
Inactive CompaniesN/A
Active IndicationsPrimary MyelofibrosisMyeloproliferative DisordersHematologic Neoplasms
Inactive IndicationsThrombocythemia, EssentialPolycythemia VeraLeukemia, Myeloid, Acute

Other Information

ATC CodeN/A
Related LinksN/A